Key result
Among Australians living with spinal muscular atrophy, 81% utilized SMN-augmenting therapies, with 47.6% of treated individuals reporting perceived improvements on the Patient/Parent Global Impression of Improvement scale.
Why the study?
New diagnosis and treatment paradigms have altered the trajectory of SMA, necessitating real-world registry data to evaluate the phenotypic and genotypic landscape, treatment patterns, and health impact in Australia.
Cross-Sectional (n=195)
Yes
Answers are grounded in this paper and cite their sources.
Despite therapeutic advances, there remains a significant unmet need for multidisciplinary care in both adults and treated children with SMA in Australia.
Background New paradigms of diagnosis and treatment have changed the neurodegenerative trajectory for individuals with spinal muscular atrophy (SMA). Registries are a critical tool to provide real-world data on treatment patterns, their effects and health care provision within this evolving paradigm of care. This study aimed to evaluate the phenotypic and genotypic landscape, treatment patterns and health impact of SMA in Australia through the national registry. Methods This cross-sectional study investigated demographic, clinical and genetic information, sequelae of weakness, treatment patterns and patient-reported outcomes amongst individuals with SMA enrolled in the Australian Neuromuscular Disease Registry (ANMDR) from 1st January 2020 to 30th April 2023. Descriptive statistics were used for analysis and Chi-Squared or Fisher's exact tests for associations. Findings 195 individuals with SMA enrolled into the ANMDR. 5/195 (2.6%) were deceased by censor date. Of (n = 190) individuals living with SMA, 104/190 (54.7%) were children. Minimum Australian prevalence was 0.73/100,000. SMN2 copies were inversely associated with phenotype in those with homozygous SMN1 deletions ( p < 0.0001 )). Treatment was utilised in 154/190 (81%) of the population, with 65/137 (47.6%) of individuals perceiving improvements with therapeutic intervention on Patient/Parent Global Impression of Improvement scale ( p < 0.0001 ). Engagement with multidisciplinary care practitioners was significantly higher among children with SMA than adults (93% versus 12%, p < 0.0001 ). Interpretation Despite diagnostic and therapeutic advances, mortality and the multi-systemic health impact of SMA continue to be experienced within the Australian population. Healthcare provision must align with patient-centred outcomes, adapting to meeting their changing but ongoing care requirements. The study identified the considerable unmet need for multidisciplinary care, not only for adults with SMA but also for the emerging cohort of treated children, emphasising the imperative for comprehensive healthcare provision to address their evolving needs. Funding No funding was received for this study.
No takes yet. Share an insight, caveat, or question.
Balaji et al. (2024) conducted a cross-sectional in Spinal muscular atrophy (n=195). SMN-augmenting therapies vs. No therapy was evaluated on Patient/Parent Global Impression of Improvement (PGI-I) (p=<0.0001). Among Australians living with spinal muscular atrophy, 81% utilized SMN-augmenting therapies, with 47.6% of treated individuals reporting perceived improvements on the Patient/Parent Global Impression of Improvement scale.
Synapse has enriched 10 related papers. Consider them for comparative context: